UY39172A - Análogos de nucleósido bi- y monocíclicos para el tratamiento de la hepatitis e - Google Patents

Análogos de nucleósido bi- y monocíclicos para el tratamiento de la hepatitis e

Info

Publication number
UY39172A
UY39172A UY0001039172A UY39172A UY39172A UY 39172 A UY39172 A UY 39172A UY 0001039172 A UY0001039172 A UY 0001039172A UY 39172 A UY39172 A UY 39172A UY 39172 A UY39172 A UY 39172A
Authority
UY
Uruguay
Prior art keywords
hepatitis
treatment
nucleoside analogues
monocyclic nucleoside
monocyclic
Prior art date
Application number
UY0001039172A
Other languages
English (en)
Inventor
Frederik Pauwels
Yannick Debing
Tim Hugo Maria Jonckers
Original Assignee
Janssen Sciences Ireland Unlimited Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Sciences Ireland Unlimited Co filed Critical Janssen Sciences Ireland Unlimited Co
Publication of UY39172A publication Critical patent/UY39172A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

La presente divulgación se refiere a análogos de nucleósido bi- y monocíclicos, composiciones que comprenden estos compuestos y su uso para tratar infecciones por hepatitis E.
UY0001039172A 2020-04-14 2021-04-13 Análogos de nucleósido bi- y monocíclicos para el tratamiento de la hepatitis e UY39172A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP20169480 2020-04-14

Publications (1)

Publication Number Publication Date
UY39172A true UY39172A (es) 2021-10-29

Family

ID=70289599

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001039172A UY39172A (es) 2020-04-14 2021-04-13 Análogos de nucleósido bi- y monocíclicos para el tratamiento de la hepatitis e

Country Status (14)

Country Link
US (1) US20230310481A1 (es)
EP (1) EP4135715B1 (es)
JP (1) JP2023522615A (es)
KR (1) KR20230002592A (es)
CN (1) CN115515603A (es)
AR (1) AR121836A1 (es)
AU (1) AU2021255809A1 (es)
BR (1) BR112022020825A2 (es)
CA (1) CA3174790A1 (es)
CL (1) CL2022002804A1 (es)
MX (1) MX2022012904A (es)
PE (1) PE20230386A1 (es)
UY (1) UY39172A (es)
WO (1) WO2021209419A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024086592A2 (en) * 2022-10-17 2024-04-25 Emory Unversity 4'-halogen containing nucleotide and nucleoside therapeutic compositions and uses related thereto

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE051986T2 (hu) * 2014-06-24 2021-04-28 Janssen Biopharma Inc Helyettesített nukleozidok, nukleotidek és analógjaik virális fertõzés kezelésére való alkalmazásra

Also Published As

Publication number Publication date
EP4135715A1 (en) 2023-02-22
KR20230002592A (ko) 2023-01-05
MX2022012904A (es) 2023-01-24
JP2023522615A (ja) 2023-05-31
CA3174790A1 (en) 2021-10-21
EP4135715B1 (en) 2024-05-08
WO2021209419A1 (en) 2021-10-21
AU2021255809A1 (en) 2022-12-15
PE20230386A1 (es) 2023-03-06
US20230310481A1 (en) 2023-10-05
CN115515603A (zh) 2022-12-23
AR121836A1 (es) 2022-07-13
BR112022020825A2 (pt) 2022-11-29
CL2022002804A1 (es) 2023-03-31
EP4135715C0 (en) 2024-05-08

Similar Documents

Publication Publication Date Title
CL2019000271A1 (es) Inhibidores de polimerasa hcv. (divisional solicitud 201600493)
CL2020001146A1 (es) Nuevas indol-2-carboxamidas sustituidas con pirazolopiperidina, de alta actividad, activas contra el virus de la hepatitis b (vhb).
CL2022003733A1 (es) Análogos de nucleósido de 1’-ciano y usos de los mismos
ECSP13010937A (es) Compuestos antivirales
ECSP20029558A (es) Nuevas indol-2-carboxamidas sustituidas con amino-tiazol, de alta actividad, activas contra el virus de la hepatitis b (vhb)
UY39027A (es) Uso de favipiravir en el tratamiento de la infección por coronavirus
ECSP18061667A (es) Pirimidinas sustituidas con arilo para su uso en la infección por virus influenza
UY38434A (es) Nuevas 6,7-dihidro-4h-pirazolo[1,5-a]pirazin indol-2-carboxamidas activas contra el virus de la hepatitis b (hbv)
CO2022014876A2 (es) Aminotiazoles sustituidos como inhibidores de dgkzeta para la activación inmune
UY35293A (es) Isotiazoles sustituidos con amino
DOP2018000183A (es) Compuesto útil para el tratamiento y la profilaxis de vih y sida y sus usos
CU24519B1 (es) Derivados de aminotiazol útiles como agentes antivíricos
CO2020005420A2 (es) Compuestos antibacterianos
ECSP21031085A (es) Nuevas 6,7-dihidro-4h-pirazolo[1,5-a] pirazinindol-2-carboxamidas activas contra el virus de la hepatitis b (vhb)
BR112023001129A2 (pt) Pró-fármacos antivirais, formulações farmacêuticas e métodos
CO2021011023A2 (es) Compuesto heterocíclico, composición farmacéutica que lo comprende, método para su preparación, y uso de estos
CL2023001062A1 (es) Compuestos fosfolípidos y usos de estos
UY39172A (es) Análogos de nucleósido bi- y monocíclicos para el tratamiento de la hepatitis e
AR117844A1 (es) Derivados de tiazolopiridina como antagonistas del receptor de adenosina
BR112023018654A2 (pt) Compostos antibacterianos
ECSP21079317A (es) Nuevas indol-2-carboxamidas activas contra el virus de la hepatitis b (vhb)
PE20181450A1 (es) Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cancer
BR112021006388A2 (pt) composto, composição farmacêutica, uso de um composto, e, método para tratamento de uma infecção viral em um mamífero
BR112023016958A2 (pt) Compostos para uso no tratamento de uma infecção por vírus envelopado
BR112022020810A2 (pt) Análogos de nucleosídeos espirocíclicos para o tratamento de hepatite e